FDA releases final guidance on tobacco product research

Aug.24.2022
FDA releases final guidance on tobacco product research
FDA releases final guide to help applicants design and conduct tobacco product intention studies.

On August 23rd, the U.S. Food and Drug Administration (FDA) released its final guidelines on guiding research into tobacco product intentions (TPPI).


Tobacco Products: Principles for Design and Implementation of Tobacco Product Intention Studies" is aimed at assisting applicants in completing studies related to the design and risk assessment of Modified Risk Tobacco Products (MRTP), Tobacco Product Marketing Applications (PMTA) including TPPI studies, or Equivalent Reports (SE) before their release to the market.


The FDA has stated that TPPI research can be used to assess individuals' views on tobacco products, understanding of tobacco product information (such as labeling and modified risk information), and intentions to use tobacco products. These studies provide crucial information during product application reviews, and this guide offers recommendations on how to conduct such research.


The Final Guidance addresses several scientific issues that applicants need to consider when designing and conducting studies on Tobacco Product Pathways of Introduction (TPPI) to support the application of tobacco products.


Developing research objectives and hypotheses, designing quantitative and qualitative research, selecting and adjusting measures of learning structure, determining research outcomes, selecting and proving research samples, and analyzing research results.


The FDA has announced that the purpose of this guidance document is to provide clarity on existing regulatory requirements for applicants. According to the agency's statement, "FDA guidance documents, including this one, should be considered as recommendations for consideration, unless specific regulatory or statutory requirements are referenced.


Announcement


This article is compiled from third-party information and is intended for industry communication and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is solely intended for industry-related communication and research purposes.


Due to the limitations of the translation skills, the translated article may not fully express the same meaning as the original. Therefore, please refer to the original article for accuracy.


2FIRSTS maintains full alignment with the Chinese government's position regarding any domestic, Hong Kong, Macao, Taiwan, or foreign-related statements and stances.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

2Firsts Exclusive Analysis | RLX Q1 Revenue Rises 96.2%, International Business Points to a More Integrated Global Strategy
2Firsts Exclusive Analysis | RLX Q1 Revenue Rises 96.2%, International Business Points to a More Integrated Global Strategy
RLX Technology’s Q1 net revenues rose 96.2% year over year, with international business accounting for 72.3% of total revenue. Beyond the headline growth, the results point to deeper globalization: European operations, Nexus supply-chain integration and a broader product portfolio are becoming key signals to watch.
Special Report
May.20
EU Launches Online Feedback as TPD Revision Enters New Milestone
EU Launches Online Feedback as TPD Revision Enters New Milestone
The European Commission has opened an online call for evidence on revising EU tobacco products and advertising rules, marking a new phase in the TPD/TAD review. Policy options may cover novel products, flavours, packaging, digital marketing and advertising. A 2Firsts review of 855 early submissions shows rapid engagement and recurring debate over differentiated regulation, harm reduction, youth protection, illicit trade and economic impact.
Special Report
May.21
BofA: U.S. Nicotine Market Splits as Vapor Sales Fall 17.2% and Oral Tobacco Rises 5.8%
BofA: U.S. Nicotine Market Splits as Vapor Sales Fall 17.2% and Oral Tobacco Rises 5.8%
According to Investing.com citing Bank of America scanner data for the four weeks ending May 30, U.S. nicotine category performance was mixed, with cigarette, vapor and cigar sales declining while oral tobacco sales rose 5.8%.
Jun.10
Special Report|U.S.-Facing Retailer Lists RELX Creator Pro 15K: A Chinese Brand Signal Under FDA’s Lower-Priority Enforcement Window
Special Report|U.S.-Facing Retailer Lists RELX Creator Pro 15K: A Chinese Brand Signal Under FDA’s Lower-Priority Enforcement Window
Vapesourcing has listed RELX Creator Pro 15K as “Coming Soon” with U.S. warehouse shipping options; while the page does not show that RELX has entered the U.S. market through official channels or that the product has received FDA authorization, the listing suggests that Chinese brand-led ENDS products are becoming a new point of observation as the U.S. market reassesses regulatory risk following the FDA’s updated enforcement-priority policy.
Industry Insight
Jun.11
2Firsts Hosts UK Vape Duty Stamp Compliance Exchange in Shenzhen
2Firsts Hosts UK Vape Duty Stamp Compliance Exchange in Shenzhen
2Firsts held a UK vape duty stamp compliance exchange in Shenzhen on May 14, bringing together representatives from nearly 20 companies. The session addressed Vaping Products Duty, duty stamp applications, UK agency qualifications and warehousing, while introducing 2Firsts Compliance Solutions’ UK service.
Events
May.17
 Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
According to Reuters, Philip Morris International (PMI) lowered its 2026 adjusted earnings-per-share forecast amid regulatory uncertainty around Zyn nicotine pouches, rising competition and shipment pressure in the U.S. market.
PMI
Jun.02